These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 33054319)

  • 21. Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration.
    Ikeda S; Sekine A; Baba T; Kato T; Katano T; Tabata E; Shintani R; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    Medicine (Baltimore); 2022 Jun; 101(22):e29232. PubMed ID: 35665728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
    Khalil N; Manganas H; Ryerson CJ; Shapera S; Cantin AM; Hernandez P; Turcotte EE; Parker JM; Moran JE; Albert GR; Sawtell R; Hagerimana A; Laurin P; Gagnon L; Cesari F; Kolb M
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
    Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
    BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
    Ntolios P; Archontogeorgis K; Anevlavis S; Bonelis K; Paxinou N; Voulgaris A; Froudarakis M; Steiropoulos P
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6326-6332. PubMed ID: 34730213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
    Loveman E; Copley VR; Scott DA; Colquitt JL; Clegg AJ; O'Reilly KM
    BMC Pulm Med; 2015 Apr; 15():37. PubMed ID: 25927225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
    Zang C; Zheng Y; Wang Y; Li L
    Eur J Med Res; 2021 Oct; 26(1):129. PubMed ID: 34717762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
    Lederer DJ; Bradford WZ; Fagan EA; Glaspole I; Glassberg MK; Glasscock KF; Kardatzke D; King TE; Lancaster LH; Nathan SD; Pereira CA; Sahn SA; Swigris JJ; Noble PW
    Chest; 2015 Jul; 148(1):196-201. PubMed ID: 25856121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
    Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
    Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis.
    Santoleri F; Auriemma L; Spacone A; Marinari S; Esposito F; De Vita F; Petragnani G; Di Fabio C; Di Fabio L; Costantini A
    J Pharm Pract; 2022 Dec; 35(6):853-858. PubMed ID: 33878986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
    Pitre T; Mah J; Helmeczi W; Khalid MF; Cui S; Zhang M; Husnudinov R; Su J; Banfield L; Guy B; Coyne J; Scallan C; Kolb MR; Jones A; Zeraatkar D
    Thorax; 2022 Dec; 77(12):1243-1250. PubMed ID: 35145039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.